Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).
Duan H, Shao C, Pan M, Liu H, Dong X, Zhang Y, Tong L, Feng Y, Wang Y, Wang L, Newman NB, Sarkaria IS, Reynolds JV, De Cobelli F, Ma Z, Jiang T, Yan X.
Duan H, et al. Among authors: zhang y.
Front Immunol. 2022 Jun 2;13:849984. doi: 10.3389/fimmu.2022.849984. eCollection 2022.
Front Immunol. 2022.
PMID: 35720388
Free PMC article.